Literature DB >> 18620638

[What do men between 50 and 70 know about the effectiveness, the benefits, and the risks of prostate cancer screening?].

Mireia Fàbregas Escurriola1, Laia Guix Font, Rosa Aragonès Forès, Josep Casajuana Brunet, Mar Ballester Torrens.   

Abstract

OBJECTIVE: To evaluate the understanding of the population on prostate cancer screening.
DESIGN: Descriptive study.
SETTING: Primary care teams in the province of Barcelona, Spain, from april to september 2005. PARTICIPANTS AND CONTEXT: Men between 50 and 70 years old without prostate symptoms and seen in the clinics of 12 primary care teams.
METHOD: Systematic sample. VARIABLES: age, marital status, educational level, and self-perceived health status. Appraisal of knowledge through a 14-question questionnaire referring to the key ideas, previously defined by a group of experts, requisite before deciding on prostate cancer screening.
RESULTS: N=221. Mean age, 59.9 (SD, 5.9); educational level, primary or lower: 63.4%; 89.1% (95% CI, 84.4-92.6) did not have sufficient knowledge about prostate cancer screening. In the questions on what PSA is and what it is for, over 50% said they did not know; 63.3% recognised that prostate cancer was a highly prevalent illness; 84.6% replied that early detection of prostate cancer avoids deaths; 49.8% did not know whether the doctor had doubts on this question; and 38.9% thought he didn't. There were no differences in knowledge for any of the variables studied.
CONCLUSIONS: Although prostate cancer screening is widely known about, the information of the population is scant and often wrong. Existing scientific uncertainty on the use of screening is the aspect that is least known by users.

Entities:  

Mesh:

Year:  2008        PMID: 18620638      PMCID: PMC7659863          DOI: 10.1157/13124129

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  11 in total

1.  Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut.

Authors:  Grace Lu-Yao; Peter C Albertsen; Janet L Stanford; Therese A Stukel; Elizabeth S Walker-Corkery; Michael J Barry
Journal:  BMJ       Date:  2002-10-05

Review 2.  Part 2: Patient information, informed decision-making and the psycho-social impact of prostate-specific antigen testing.

Authors:  Paul Hewitson; Joan Austoker
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

3.  [Hospitalizations by ambulatory care sensitive conditions (ACSC) from the general practitioner/family physician's point of view].

Authors:  Juan Gérvas; Josefina Caminal Homar
Journal:  Rev Esp Salud Publica       Date:  2007 Jan-Feb

4.  [Comprension of a document informing citizens as to the benefits and risks of prostate cancer screening. A semistructured interview-based study].

Authors:  M José Fernández de Sanmamed Santos; Mar Ballester Torrens; Ferran Ariza González; Josep Casajuana Brunet
Journal:  Rev Esp Salud Publica       Date:  2007 May-Jun

5.  Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.

Authors:  Ingrid W van der Cruijsen-Koeter; Monique J Roobol; Mark F Wildhagen; T H van der Kwast; W J Kirkels; Fritz H Schröder
Journal:  Urology       Date:  2006-09       Impact factor: 2.649

Review 6.  Reduction in uptake of PSA tests following decision aids: systematic review of current aids and their evaluations.

Authors:  Rhodri Evans; Adrian Edwards; Joanne Brett; Mike Bradburn; Eila Watson; Joan Austoker; Glyn Elwyn
Journal:  Patient Educ Couns       Date:  2005-07

7.  Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?

Authors:  K J O'Dell; R J Volk; A R Cass; S J Spann
Journal:  J Fam Pract       Date:  1999-09       Impact factor: 0.493

Review 8.  Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force.

Authors:  Russell Harris; Kathleen N Lohr
Journal:  Ann Intern Med       Date:  2002-12-03       Impact factor: 25.391

9.  What should men know about prostate-specific antigen screening before giving informed consent?

Authors:  E C Chan; D P Sulmasy
Journal:  Am J Med       Date:  1998-10       Impact factor: 4.965

10.  Measuring patient knowledge of the risks and benefits of prostate cancer screening.

Authors:  David M Radosevich; Melissa R Partin; Sean Nugent; David Nelson; Ann Barry Flood; Jeremy Holtzman; Nancy Dillon; Michele Haas; Timothy J Wilt
Journal:  Patient Educ Couns       Date:  2004-08
View more
  2 in total

1.  [Doctor, with your knowledge of medicine and health care and me, tell me, what would you do in my place?].

Authors:  Juan Simó Miñana
Journal:  Aten Primaria       Date:  2011-09-22       Impact factor: 1.137

2.  Prevention and clinical complexity.

Authors:  Juan Gérvas; Iona Heath; Antonio Durán; Joan Gené
Journal:  Aten Primaria       Date:  2009-05-21       Impact factor: 1.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.